ClinicalTrials.gg
Not yet recruitingNCT07949877Updated Nov 19, 2026

Clinical Significance of the IL-33-ACOD1-MARCO Axis in HBV-Related Acute-on-Chronic Liver Failure

An observational study in HBV-Related Cirrhosis, HBV-Related Acute-on-Chronic Liver Failure and Chronic Hepatitis B, sponsored by Minghui Li. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Minghui Li · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 378 studies in Hepatitis B, Chronic with a site in China — 91 open to participants now, 112 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
95th of 101
80 · median 500
Started
2026
with 28 others
Observational
101 of 378
35 open now
Primary completion
2027-05
later than 64 of 111 live
Registered
378th of 378
by date

Among the 378 studies in Hepatitis B, Chronic with a site in China, this one is the 95th largest by planned enrollment of the 101 observational ones that give a count, is one of 29 that started in 2026, is one of 101 observational ones, reaches primary completion later than 64 of the 111 other live ones, and was the 378th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

91 of the 378 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 378 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This single-center, prospective observational study will enroll 80 adults: 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-related acute-on-chronic liver failure (HBV-ACLF). The study will not assign any research treatment, and all participants will continue to receive routine clinical care. A 5 mL peripheral blood sample will be collected once from the first three groups. Participants with HBV-ACLF will have 5 mL blood collected at baseline, Day 28, and Day 90, and their 28-day and 90-day survival status will be recorded. Plasma IL-33, IL-6, TNF-alpha, and IL-10 will be measured. Peripheral blood CD14-positive monocytes will be isolated, and ACOD1 and MARCO mRNA expression will be measured by quantitative PCR. The study will compare these markers across groups and assess their relationships with inflammation, disease severity, longitudinal clinical changes, and short-term outcomes.

Read the detailed description

HBV-related acute-on-chronic liver failure is characterized by rapid clinical deterioration, systemic inflammation, and high short-term mortality. Previous experimental work in a mouse model of immune-mediated liver injury suggested that IL-33 may induce ACOD1 expression in hepatic macrophages and increase MARCO expression through an itaconate-related pathway, thereby enhancing efferocytosis and reducing inflammatory injury. The complete IL-33-ACOD1-MARCO axis has not been established in patients, and measurements in peripheral blood CD14-positive monocytes cannot be considered direct measurements of liver-resident macrophage function.

This study combines a cross-sectional comparison with longitudinal follow-up. At baseline, plasma IL-33 and inflammatory cytokines and CD14-positive monocyte ACOD1 and MARCO mRNA expression will be compared among healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-ACLF. In the HBV-ACLF group, associations with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, IL-6, TNF-alpha, and IL-10 will be evaluated. Participants with HBV-ACLF will undergo follow-up at Day 28 and Day 90 to assess biomarker changes, all-cause mortality, and liver transplantation status.

Blood will be collected in EDTA-K2 tubes and processed within 2 hours. Plasma IL-33 will be measured by ELISA, and IL-6, TNF-alpha, and IL-10 will be measured by Luminex. Peripheral blood mononuclear cells will be isolated by Ficoll density-gradient centrifugation, followed by CD14-positive magnetic-bead selection and flow-cytometric verification of purity. ACOD1 and MARCO mRNA expression will be measured by quantitative PCR using GAPDH as the reference gene and the 2\^-DeltaDeltaCt method.

03

Conditions studied

  • HBV-Related Cirrhosis
  • HBV-Related Acute-on-Chronic Liver Failure
  • Chronic Hepatitis B

Browse trials for

Keywords

  • MARCO
  • CD14-Positive Monocytes
  • Efferocytosis
  • Immune-Mediated Liver Injury
  • Interleukin-33
  • ACOD1
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adults aged 18 to 70 years will be recruited at Beijing Ditan Hospital, Capital Medical University. The study population will include healthy individuals undergoing routine health examinations and patients receiving care at the Liver Disease Center for chronic hepatitis B, HBV-related cirrhosis, or HBV-related acute-on-chronic liver failure. Individuals who meet the applicable group definition and the inclusion and exclusion criteria will be enrolled after providing written informed consent. The planned enrollment is 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-ACLF.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 70 years, regardless of sex.
  • Meets the criteria for one of the following study groups:

Healthy Control Group: No history of liver disease, negative surface antigen (HBsAg), and normal liver function.

Chronic Hepatitis B Group: HBsAg positivity for more than 6 months, no imaging evidence of cirrhosis, and does not meet the diagnostic criteria for HBV-related acute-on-chronic liver failure (HBV-ACLF).

HBV-Related Cirrhosis Group: HBsAg positivity for more than 6 months and cirrhosis confirmed by imaging or pathological examination, without meeting the diagnostic criteria for HBV-ACLF.

HBV-ACLF Group: HBsAg positivity for more than 6 months and meets the COSSH-ACLF diagnostic criteria.

-Fully understands the study and voluntarily provides written .

Exclusion criteria

Exclusion Criteria:

  • Coinfection with hepatitis A, C, D, or E virus, or the presence of another liver disease, including liver disease, drug-induced liver injury, or alcohol-related liver disease.
  • Confirmed hepatocellular carcinoma.
  • Pregnancy or breastfeeding.
  • Treatment with agents or high-dose within 4 weeks before enrollment.
  • infection.
  • Severe renal impairment, defined as an estimated below 30 mL/min/1.73 m².
  • Incomplete key clinical data at enrollment or an anticipated inability to complete the study sampling and follow-up required for the assigned group.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Healthy Control

    Adults without a history of liver disease, with negative hepatitis B surface antigen and normal liver function. Participants will undergo one study blood collection at enrollment.

  • Chronic Hepatitis B

    Adults with hepatitis B surface antigen positivity for more than 6 months, without imaging evidence of cirrhosis and not meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection.

  • HBV-Related Cirrhosis

    Adults with chronic HBV infection and cirrhosis confirmed by imaging or pathology, without meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection.

  • HBV-Related Acute-on-Chronic Liver Failure

    Adults with hepatitis B surface antigen positivity for more than 6 months who meet the COSSH-ACLF diagnostic criteria. Participants will undergo study blood collection at baseline, Day 28, and Day 90 and will be followed for 28-day and 90-day survival outcomes.

06

What researchers measure

Primary outcomes

  1. Plasma IL-33 Concentration at Baseline Across Study Groups

    Plasma IL-33 concentration will be measured in EDTA plasma by enzyme-linked immunosorbent assay (ELISA) in healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-related acute-on-chronic liver failure.

    Time frame: Baseline (at enrollment or hospital admission)

  2. ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups

    Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. ACOD1 mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2\^-DeltaDeltaCt method.

    Time frame: Baseline (at enrollment or hospital admission)

  3. MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups

    Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. MARCO mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2\^-DeltaDeltaCt method.

    Time frame: Baseline (at enrollment or hospital admission)

Secondary outcomes

  1. Correlation of Plasma IL-33 With ACOD1 and MARCO mRNA Expression in Participants With HBV-ACLF

    At baseline in participants with HBV-related acute-on-chronic liver failure, Spearman correlation coefficients will be calculated between plasma IL-33 concentration and ACOD1 and MARCO mRNA relative expression in peripheral blood CD14-positive monocytes.

    Time frame: Baseline

  2. Association of ACOD1 and MARCO mRNA Expression With Disease Severity and Inflammatory Markers in Participants With HBV-ACLF

    At baseline in participants with HBV-related acute-on-chronic liver failure, correlations of ACOD1 and MARCO mRNA relative expression with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, plasma IL-6, TNF-alpha, and IL-10 will be assessed.

    Time frame: Baseline

  3. 28-Day All-Cause Mortality in Participants With HBV-ACLF

    Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death.

    Time frame: From baseline through Day 28

  4. 90-Day All-Cause Mortality in Participants With HBV-ACLF

    Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death.

    Time frame: From baseline through Day 90

  5. Change in Plasma IL-33 Concentration in Participants With HBV-ACLF

    Plasma IL-33 concentration will be measured by ELISA at baseline, Day 28, and Day 90. Within-participant changes over time will be described and analyzed using repeated-measures methods specified in the protocol.

    Time frame: Baseline, Day 28, and Day 90

  6. Change in ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF

    ACOD1 mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2\^-DeltaDeltaCt method.

    Time frame: Baseline, Day 28, and Day 90

  7. Change in MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF

    MARCO mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2\^-DeltaDeltaCt method.

    Time frame: Baseline, Day 28, and Day 90

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

Of 72 observational studies under Hepatitis B, Chronic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 99. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949877
Lead sponsor
Minghui Li
Responsible party
Minghui Li (Head of Department, Beijing Municipal Administration of Hospitals) — Sponsor-investigator
First posted
Nov 19, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion